erlotinib hydrochloride has been researched along with Adrenocortical Carcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lian, J; Ning, G; Qi, Y; Wang, W; Wang, X; Xu, L; Xu, Y; Zhu, Y | 1 |
| Adam, P; Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Quinkler, M; Ritte, C; Ritter, C; Strasburger, C; Wortmann, S | 1 |
1 trial(s) available for erlotinib hydrochloride and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Routes; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Salvage Therapy; Treatment Outcome | 2008 |
1 other study(ies) available for erlotinib hydrochloride and Adrenocortical Carcinoma
| Article | Year |
|---|---|
Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Mice, Nude; Middle Aged; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Xenograft Model Antitumor Assays | 2016 |